• Professor Ruth V. Aguilera, PhD, Northeastern University, Trustee Professor at the D’Amore-McKim School of Business, Boston, Massachusetts, USA
  • Mark Treherne, PhD, Chairperson, Monument Therapeutics, Cambridge, UK, and Curriculum Coordinator, Biotechnology Business Institute, Cambridge, UK

Marblehead, MA, September 12, 2023 – The Communications Strategy Group Inc. (CSG), a Boston area life sciences consultancy, today announced that Professor Ruth V. Aguilera, PhD, and Mark Treherne, PhD, have joined the Company’s Advisory Board, reflecting CSG’s growing international presence as European companies seek advice and assistance in reaching US customers, investors, and potential partners.

Commenting on the appointments, CSG President Ted Agne said, “We’ve seen a sharp up-tick in European clients wanting a higher US profile. There is growing awareness among them that effective communications and business development programs are needed to thrive in the US. These companies realize that building awareness in the US and making the right connections is essential for success. Professor Aguilera and Dr.Treherne bring tremendous business experience, scientific knowledge, and perspective to our practice greatly enhancing what we can do for our clients in Europe and the US. My colleagues and I look forward to working closely with them in the years ahead.”

Professor Ruth V. Aguilera

Ruth V. Aguilera (Harvard University, PhD) is the Distinguished Darla and Frederick Brodsky Trustee Professor at the D’Amore-McKim School of Business at Northeastern University in Boston, Massachusetts, and a Visiting Professor at ESADE Business School in her native Barcelona. Aguilera’s research, teaching and consulting interests focus on international corporate governance and corporate social responsibility/sustainability.  She has published close to 100 academic and professional articles, and two books. Since 2019, she has been consecutively ranked by the “Thompson Reuter’s and Clarivate Analytics” among the top 100 Most Highly Cited Researchers in Economics and Business in the world.

Professor Aguilera serves on the board of Primport-Trade in Spain, and as the Chair of the Board of Directors of the International Corporate Governance Society. She also serves on the International Advisory Committees of Rennes School of Business in France, IAE Business School in Argentina, Indian Institute of Management Bangalore (India), and ESADE Center of Corporate Governance, and until recently served on the board of the Strategic Management Society, where she chaired two key committees during her six-year, two-term appointment. Professor Aguilera is one of six worldwide triple Fellows at two prestigious academic organizations in her field, the Academy of International Business and the Strategic Management Society.

Professor Aguilera teaches international business, global strategy, and corporate governance in multiple programs: undergraduate, graduate and executive. In addition, she advises and teaches strategy and best practices in corporate governance across a variety of organizations ranging from family firms in Mexico, Peru and Spain to multinational firms such as Iberdrola in Madrid, Archer Daniels Midland in Chicago, and the Federation of International Automobile (FIA) in London. She also regularly teaches in the High-performance Boards programs at the Institute for Management Development (IMD) in Switzerland and ESADE in Spain.

Mark Treherne, PhD

Mark Treherne has more than thirty years of practical experience in the discovery of novel treatments for human disease, originally in academia but mostly in industry. At Pfizer, he was responsible for research into neurodegenerative diseases in the UK, after which he left to set up Cambridge Drug Discovery in 1997.

Since then, Dr. Treherne has helped raise more than £300 million (almost $400 million USD) for a series of early-stage life sciences companies and served on the boards of multiple therapeutics and diagnostics companies worldwide. He has worked with teams to out-license therapeutic assets over the last twenty years for upfront payments, milestones and future royalties exceeding £1.5 billion.

Dr. Treherne earned a PhD from the University of Cambridge in 1987 and has also taught at the Universities of Basel and Kent. Since 1984, he has published more than ninety articles in peer-reviewed scientific journals and in the commercial trade press. He currently serves as the Curriculum Coordinator at the Biotechnology Business Institute, Cambridge, UK, and Barcelona, Spain, and is the Chairperson at Monument Therapeutics, Cambridge.

About The Communications Strategy Group Inc.

The Communications Strategy Group Inc. is a consulting firm offering a full slate of external communications and business development services to emerging and later-stage companies in life sciences, biotechnology, health care and advanced technologies.

Headquartered in the Boston area with offices in Washington, DC, and  Advance, North Carolina, the CSG team is composed of senior-level consultants with expertise in market research and analysis; domestic and international major media relations; writing support; Web content; financial relations; crisis and issues management; litigation communications management; business development and start-up company assistance, including fundraising, risk sharing and mentoring; UK government relations, and UK/EU business development. In Europe. CSG is partnered with Zyme Communications, Cambridge, UK, and Cabinet Privé de Conseils s.a., Geneva. CSG was founded in 1987 by Ted Agne, the current president.

Media Contacts

Ted Agne
+1781 888 0099

Frank Pietrucha
+1202 253 7376